These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 8416161)
1. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Giugliano D; Marfella R; Quatraro A; De Rosa N; Salvatore T; Cozzolino D; Ceriello A; Torella R Ann Intern Med; 1993 Jan; 118(1):7-11. PubMed ID: 8416161 [TBL] [Abstract][Full Text] [Related]
2. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. Didangelos TP; Karamitsos DT; Athyros VG; Kourtoglou GI J Diabetes Complications; 1998; 12(4):201-7. PubMed ID: 9647338 [TBL] [Abstract][Full Text] [Related]
3. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611 [TBL] [Abstract][Full Text] [Related]
4. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group. Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610 [TBL] [Abstract][Full Text] [Related]
5. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group. Macleod AF; Boulton AJ; Owens DR; Van Rooy P; Van Gerven JM; Macrury S; Scarpello JH; Segers O; Heller SR; Van Der Veen EA Diabete Metab; 1992; 18(1):14-20. PubMed ID: 1563531 [TBL] [Abstract][Full Text] [Related]
6. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. Jaspan JB; Herold K; Bartkus C Am J Med; 1985 Nov; 79(5A):24-37. PubMed ID: 3000176 [TBL] [Abstract][Full Text] [Related]
7. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy. van Gerven JM; Lemkes HH; van Dijk JG J Diabetes Complications; 1992; 6(1):45-8. PubMed ID: 1562758 [TBL] [Abstract][Full Text] [Related]
8. Tolrestat in the primary prevention of diabetic neuropathy. Giugliano D; Acampora R; Marfella R; Di Maro G; De Rosa N; Misso L; Ceriello A; Quatraro A; D'Onofrio F Diabetes Care; 1995 Apr; 18(4):536-41. PubMed ID: 7497865 [TBL] [Abstract][Full Text] [Related]
9. Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy. Fabiani F; De Vincentis N; Staffilano A Diabete Metab; 1995 Dec; 21(5):360-4. PubMed ID: 8586153 [TBL] [Abstract][Full Text] [Related]
10. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Jaspan JB; Towle VL; Maselli R; Herold K Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212 [TBL] [Abstract][Full Text] [Related]
11. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Boulton AJ; Levin S; Comstock J Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323 [TBL] [Abstract][Full Text] [Related]
13. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?]. Daniele E; Coco MP Clin Ter; 1995 Dec; 146(12):793-99. PubMed ID: 8681499 [TBL] [Abstract][Full Text] [Related]
14. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. Sundkvist G; Armstrong FM; Bradbury JE; Chaplin C; Ellis SH; Owens DR; Rosén I; Sönksen P J Diabetes Complications; 1992; 6(2):123-30. PubMed ID: 1611136 [TBL] [Abstract][Full Text] [Related]
15. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Ziegler D; Mayer P; Rathmann W; Gries FA Diabetes Res Clin Pract; 1991 Oct; 14(1):63-73. PubMed ID: 1748064 [TBL] [Abstract][Full Text] [Related]
16. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376 [TBL] [Abstract][Full Text] [Related]
17. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Gill JS; Williams G; Ghatei MA; Hetreed AH; Mather HM; Bloom SR Diabete Metab; 1990; 16(4):296-302. PubMed ID: 2125013 [TBL] [Abstract][Full Text] [Related]
18. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. van Gerven JM; Boot JP; Lemkes HH; van Best JA Doc Ophthalmol; 1994; 87(4):355-65. PubMed ID: 7851219 [TBL] [Abstract][Full Text] [Related]
19. [Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients]. Terranova R; Luca S Minerva Med; 1993 Sep; 84(9):461-6. PubMed ID: 8247317 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data. Nicolucci A; Carinci F; Graepel JG; Hohman TC; Ferris F; Lachin JM Diabetes Care; 1996 Oct; 19(10):1091-6. PubMed ID: 8886554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]